Abbas, Faisal https://orcid.org/0000-0003-2323-278X
Salehian, Mohammad https://orcid.org/0000-0003-4073-292X
Hou, Peter https://orcid.org/0000-0001-5166-8869
Moores, Jonathan https://orcid.org/0009-0004-7119-0347
Goldie, Jonathan
Tsioutsios, Alexandros https://orcid.org/0009-0006-7633-4666
Tait, Theo https://orcid.org/0009-0004-6891-3794
Portela, Victor https://orcid.org/0000-0001-9636-6573
Boulay, Quentin
Thiolliere, Roland
Stark, Ashley
Schwartz, Jean-Jacques https://orcid.org/0009-0004-7879-2877
Guerin, Jerome
Maloney, Andrew G. P. https://orcid.org/0000-0002-2578-9293
Moldovan, Alexandru A. https://orcid.org/0000-0003-2776-3879
Reynolds, Gavin K. https://orcid.org/0000-0002-9592-8228
Mantanus, Jérôme
Clark, Catriona
Chapman, Paul https://orcid.org/0000-0002-6390-5558
Florence, Alastair https://orcid.org/0000-0002-9706-8364
Markl, Daniel https://orcid.org/0000-0003-0411-733X
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (EP/V062077/1)
RCUK | Engineering and Physical Sciences Research Council (EP/R032858/1)
RCUK | Engineering and Physical Sciences Research Council (EP/P006965/1)
Research England and the Scottish Funding Council under the UK Research Partnership Investment Fund Net Zero Medicines Manufacturing Research Pilot.
Article History
Received: 28 February 2025
Accepted: 16 March 2026
First Online: 1 April 2026
Competing interests
: G.K.R. reports a relationship with AstraZeneca that includes: employment and equity or stocks. Apart from this, the authors declare no competing interests.